Editorial commentary: Challenges of sexually transmitted disease prevention and control: No magic bullet, but some bullets would still be appreciated

Clinical Infectious Diseases

Volumn 41, Issue 6, 2005, Pages 804-807

  DeMaria Jr , Alfred ^a  

^a MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CEFIXIME; CEFPODOXIME PROXETIL; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DOXYCYCLINE; LEVOFLOXACIN; OFLOXACIN; PENICILLIN G; PROBENECID; PROCAINE PENICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; SULFONAMIDE; TETRACYCLINE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; DRUG USE; ETHNIC GROUP; GONORRHEA; HETEROSEXUALITY; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; NEISSERIA GONORRHOEAE; NONHUMAN; NOTE; PRIORITY JOURNAL; PUBLIC HEALTH; RACE; RISK FACTOR; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UNITED STATES; MICROBIOLOGY; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GONORRHEA; HUMANS;

EID: 24644497119     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432810     Document Type: Note

References (23)

1. Brandt AM. No magic bullet: a social history of venereal disease in the united states since 1880. Expanded ed. New York: Oxford University Press, 1987.
2. Bauer HM, Mark KE, Samuel M, et al. Prevalence of and associated risk factors for fluoroquinolone-resistant Neisseria gonorrhoeae in California, 2000-2003. Clin Infect Dis 2005; 41:795-803 (in this issue).
3. Jaffe HW, Biddle JW, Johnson SP, Wiesner PJ. Infections due to penicillinase-producing Neisseria gonorrhoeae in the United States: 1976-1980. J Infect Dis 1981; 144:191-7.
4. Iverson CJ, Wang SA, Lee MV, et al. Fluoroquinolone resistance among Neisseria gonorrhoeae isolates in Hawaii, 1990-2000: role of foreign importation and increasing endemic spread. Sex Transm Dis 2004; 31:702-8.
5. Forsyth A, Moyes A, Young H. Increased ciprofloxacin resistance in gonococci isolated in Scotland. Lancet 2000; 356:1984-5.
6. Fenton KA, Ison C, Johnson AP, et al. Ciprofloxacin resistance in Neisseria gonorrhoeae in England and Wales in 2002. Lancet 2003; 361:1867-9.
7. Gordon SM, Carlyn CJ, Doyle LJ, et al. The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: epidemiology and risk factors. Ann Intern Med 1996; 125:465-70.
8. Kilmarx PH, Knapp JS, Xia M, et al. Intercity spread of gonococci with decreased susceptibility to fluoroquinolones: a unique focus in the United States. J Infect Dis 1998; 177:677-82.
9. Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2003 supplement: Gonococcal Isolate Surveillance Project (GISP) annual report-2003. Atlanta, GA: US Department of Health and Human Services, 2004.
10. Faruki H, Kohmescher RN, McKinney WP, Sparling PF. A community-based outbreak of infection with penicillin-resistant Neisseria gonorrhoeae not producing penicillinase (chromosomally mediated resistance). N Engl J Med 1985; 313:607-11.
11. Knapp JS, Zenilman JM, Biddle JW, et al. Frequency and distribution in the United States of strains of Neisseria gonorrhoeae with plasmid-mediated, high-level resistance to tetracycline. J Infect Dis 1987; 155:819-22.
12. Rothenberg R. STD transmission dynamics: some current complexities. 2002 Thomas Parran Award Lecture. Sex Transm Dis 2003; 30:478-82.
13. Doherty IA, Padian NS, Marlow C, Aral SO. Determinants and consequences of sexual networks as they affect the spread of sexually transmitted infections. J Infect Dis 2005; 191(Suppl 1):S42-54.
14. Mahoney JF, Ferguson C, Buchholtz M, et al. The use of penicillin sodium in the treatment of sulfonamide-resistant gonorrhea in men: a preliminary report. Am J Syph Gonorrhea Vener Dis 1943; 27:525-8.
15. Veneral Disease Advisory Committee. Gonorrhea-CDC recommended treatment schedules, 1974. MMWR Morb Mortal Weekly Rep 1974; 23:341-2.
16. Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987; 317:272-8.
17. Centers for Disease Control and Prevention. STD treatment guidelines. MMWR Morbid Mortal Weekly Rep 1985; 34(Suppl 4):75S-109S.
18. Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. MMWR Morbid Mortal Weekly Rep 1993; 42:(RR-14):56-67.
19. Centers for Disease Control and Prevention. 1998 guidelines for treatment of sexually transmitted diseases. MMWR Morbid Mortal Weekly Rep 1998; 47:(RR-1):59-69.
20. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Morbid Mortal Weekly Rep 2002; 51:(RR-6):36-42.
21. Judson FN, Ehret JM, Handsfield HH. Comparative study of ceftriaxone and spectinomycin for treatment of pharyngeal and anorectal gonorrhea. JAMA 1985; 253:1417-9.
22. Centers for Disease Control and Prevention. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men- United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Morbid Mortal Weekly Rep 2004; 53:335-8.
23. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates...a public health crisis brews. Alexandria, VA: Infectious Diseases Society of America, 2004. Available at: http://www.idsociety .org/badbugsnodrugs. Accessed 11 July 2005.